151 related articles for article (PubMed ID: 34144176)
1. Single-Dose Human Papillomavirus Vaccination in Low- and Middle-Income Countries-Time for Implementation?
Gallant D; Tummers P; Weyers S; Merckx M
J Pediatr Adolesc Gynecol; 2021 Oct; 34(5):586-590. PubMed ID: 34144176
[TBL] [Abstract][Full Text] [Related]
2. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
Spayne J; Hesketh T
BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
[TBL] [Abstract][Full Text] [Related]
3. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the barriers to implementing human papillomavirus vaccination programs in low- and middle-income countries in the Asia-Pacific.
Ver AT; Notarte KI; Velasco JV; Buac KM; Nazareno J; Lozañes JA; Antonio D; Bacorro W
Asia Pac J Clin Oncol; 2021 Dec; 17(6):530-545. PubMed ID: 33636046
[TBL] [Abstract][Full Text] [Related]
5. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013.
Ladner J; Besson MH; Rodrigues M; Audureau E; Saba J
BMC Public Health; 2014 Jun; 14():670. PubMed ID: 24981818
[TBL] [Abstract][Full Text] [Related]
6. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
[TBL] [Abstract][Full Text] [Related]
7. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy.
Sankaranarayanan R
Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 1():S33-5. PubMed ID: 26433502
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.
Ebrahimi N; Yousefi Z; Khosravi G; Malayeri FE; Golabi M; Askarzadeh M; Shams MH; Ghezelbash B; Eskandari N
Front Immunol; 2023; 14():1150238. PubMed ID: 37261366
[TBL] [Abstract][Full Text] [Related]
9. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.
Tsu VD; LaMontagne DS; Atuhebwe P; Bloem PN; Ndiaye C
Prev Med; 2021 Mar; 144():106335. PubMed ID: 33678232
[TBL] [Abstract][Full Text] [Related]
10. Integration of other services with human papillomavirus vaccination; lessons from earlier in the life course highlight the need for new policy and implementation evidence.
Morgan C; Giattas MR; Holroyd T; Pfitzer A; Engel D; Sidibe A; Holloway M; Bloem P; Fields R; Shimp L; Kumar S
Vaccine; 2022 Mar; 40 Suppl 1():A94-A99. PubMed ID: 35105493
[TBL] [Abstract][Full Text] [Related]
11. Human papilloma virus vaccine for low and middle income countries: A step too soon?
Jindal HA; Kaur A; Murugan S
Hum Vaccin Immunother; 2017 Nov; 13(11):2723-2725. PubMed ID: 28846491
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
13. Options for design of real-world impact studies of single-dose vaccine schedules.
Franceschi S; Clifford GM; Baussano I
Vaccine; 2018 Aug; 36(32 Pt A):4816-4822. PubMed ID: 29571973
[TBL] [Abstract][Full Text] [Related]
14. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
16. Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.
Okeah BO; Ridyard CH
Appl Health Econ Health Policy; 2020 Oct; 18(5):641-654. PubMed ID: 32468410
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.
Fesenfeld M; Hutubessy R; Jit M
Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973
[TBL] [Abstract][Full Text] [Related]
18. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
[TBL] [Abstract][Full Text] [Related]
19. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.
Bruni L; Diaz M; Barrionuevo-Rosas L; Herrero R; Bray F; Bosch FX; de Sanjosé S; Castellsagué X
Lancet Glob Health; 2016 Jul; 4(7):e453-63. PubMed ID: 27340003
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
